Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.
Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance]